Cargando…
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Immunotherapy has recently emerged as a novel strategy for treating different types of solid tumors, with promising results. However, still a large fraction of patients do not primarily respond to such approaches, and even responders sooner or later develop resistance. Moreover, immunotherapy is a p...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141336/ https://www.ncbi.nlm.nih.gov/pubmed/32138216 http://dx.doi.org/10.3390/jcm9030675 |